Q1 Earnings Forecast for ADAP Issued By Zacks Small Cap

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research report issued on Tuesday, March 25th. Zacks Small Cap analyst M. Kim anticipates that the biotechnology company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Zacks Small Cap also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The firm had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million.

A number of other research firms also recently issued reports on ADAP. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Friday, March 21st. They issued a “buy” rating for the company. Guggenheim lowered their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Scotiabank cut their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Trading Down 4.4 %

ADAP stock opened at $0.22 on Thursday. Adaptimmune Therapeutics has a 52 week low of $0.22 and a 52 week high of $1.65. The company has a market capitalization of $56.29 million, a PE ratio of -1.00 and a beta of 2.52. The company’s 50-day simple moving average is $0.51 and its 200 day simple moving average is $0.68. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ADAP. Two Seas Capital LP bought a new stake in Adaptimmune Therapeutics during the fourth quarter worth $7,992,000. Two Sigma Investments LP raised its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after buying an additional 58,787 shares during the last quarter. Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 152,780 shares in the last quarter. Finally, Long Focus Capital Management LLC grew its position in Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.